The EU has set aside a €100 million block of financing for small- and medium-sized enterprises working on projects that could tackle public health threats, including emerg
The recent hospitalisation of Madonna once again highlights the risks posed by bacterial infections and their potentially serious consequences for patients.
The yearly subscription-style payments made by NHS England to developers of novel antibiotics could be doubled from £10 million to £20 million in some cases, according to
F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candi
